Maxim Group Maintains Buy Rating on Scienture Holdings, Lowers Price Target
Maxim Group analyst Naz Rahman maintained a 'Buy' rating on Scienture Holdings while adjusting the price target from $37.50 to $6.00.
Stocks · News reference
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Three U.S. pediatric hospitals added Scienture's hypertension drug Arbli to their formularies, boosting institutional reach.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Scienture Holdings Issues Shareholder Letter Highlighting Financial and Commercial Progress
Scienture Holdings, Inc. released a letter to shareholders detailing a 256% sequential revenue growth for the first nine months of 2026 and progress toward 2027 profitability.
8-K filing — Scienture Holdings, Inc. (SCNX)
Filed: 2026-10-19 AccNo: 0001493152-26-047579 Size: 269 KB Item 2.02: Results of Operations and Financial Condition Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits
Scienture Holding shares are trading lower despite reporting preliminary Q3 revenue of $1.22 million, up 256% sequentially.
SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers
EXCLUSIVE: Scienture Reports Preliminary Q3 Sales of ~$1.22M, Sequential Growth of 256%, Arbli Wholesale Unit Sales Increased 74% Sequentially